Market Tracker

12/02 5:16pm ET

Navidea Biopharmaceuticals Inc (NYSE MKT LLC:NAVB)

0.71
Delayed Data
As of Dec 02
 -0.0131 / -1.81%
Today’s Change
0.26
Today|||52-Week Range
1.53
-46.62%
Year-to-Date
Company News for November 28, 2016
Nov 28 / Zacks.com - Paid Partner Content
Cardinal Health to Acquire Lymphoseek Rights for $80 Million
Nov 25 / Zacks.com - Paid Partner Content
Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health
Nov 25 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close0.72
Today’s open0.71
Day’s range0.70 - 0.73
Volume893,399
Average volume (3 months)1,783,651
Market cap$110.6M
Dividend yield--
Data as of 3:58pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)+25.00%
Earnings growth (this year)+55.56%
Earnings growth (next 5 years)--
Revenue growth (last year)+111.15%
P/E ratioNM
Price/Sales15.18
Price/Book--

Competitors

 Today’s
change
Today’s
% change
FBIOFortress Biotech Inc+0.03+1.34%
ECYTEndocyte Inc-0.02-0.75%
KURAKura Oncology Inc-0.40-7.21%
MSLIMerus Labs Internati...-0.05-4.99%
Data as of 4:00pm ET, 12/02/2016

Financials

Next reporting dateMarch 9, 2017
EPS forecast (this quarter)-$0.01
Annual revenue (last year)$13.2M
Annual profit (last year)-$27.6M
Net profit margin-213.76%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mike M. Goldberg
Chief Operating &
Financial Officer
Jed Andrew Latkin
Corporate headquarters
Dublin, Ohio

Forecasts